glp-1 agonist gastroparesis receptor agonists are increasingly used to treat type 2 diabetes and obesity, and trials have shown reductions in cardiovascular risk and slowing of kidney failure. Adverse events are mostly gastrointestinal Researchers find GLP-1 medications safe
Description
Hone your obesity medicine skills in primary care
(2021) 33:83344.e5
Endogenous hindbrain glucagon-like peptide-1 receptor activation contributes to the control of food intake by mediating gastric satiation signaling
Close monitoring over time Regular followup visits to track weight, body composition, labs, blood pressure, and side effects
2025;8(8):e2526327
Clinical pharmacokinetics of oral semaglutide
